Recurrent Urinary Tract Infections: Uro-Vaxom®, a New Alternative

European Urology, Supplements

Volumn 8, Issue 9, 2009, Pages 762-768

  Cruz, Francisco ^a   Dambros, Miriam ^b   Naber, Kurt G ^c   Bauer, Hartwig W ^d   Cozma, Gabriel ^e  

^a HOSPITAL DE SÃO JOÃO   (Portugal)

^b UNIVERSITY OF CAMPINAS   (Brazil)

^c TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^d LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^e Vifor (International) Inc   (Switzerland)

Author keywords

Antibacterial agents; Cystitis; Immunostimulant; Microbial drug resistance; OM 89; Prophylaxis; Recurrence; Urinary tract infections; Uro Vaxom

Indexed keywords

AMPICILLIN; COTRIMOXAZOLE; ESCHERICHIA COLI VACCINE; ESTRIOL; FOSFOMYCIN; FOSFOMYCIN TROMETAMOL; GAMMA INTERFERON; INTERLEUKIN 12; MECILLINAM; NITROFURANTOIN; OM 89; PLACEBO; PROBIOTIC AGENT; QUINOLONE DERIVATIVE; STROVAC; TRIMETHOPRIM; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; URO VAXOM;

ANTIBIOTIC PROPHYLAXIS; ANTIBIOTIC RESISTANCE; CHRONIC PROSTATITIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CRANBERRY JUICE; CYSTITIS; DRUG ABSORPTION; DRUG EFFICACY; DRUG MECHANISM; DRUG SENSITIVITY; DRUG TOLERABILITY; GASTROINTESTINAL DISEASE; HEARTBURN; HUMAN; IMMUNIZATION; IMMUNOSTIMULATION; NAUSEA; NEWBORN DISEASE; NONHUMAN; PATIENT MONITORING; POSTMENOPAUSE; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENT INFECTION; REVIEW; SHORT COURSE THERAPY; TREATMENT FAILURE; URINARY TRACT INFECTION; URINE ACIDIFICATION;

EID: 68949172258     PISSN: 15699056     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eursup.2009.07.002     Document Type: Review

References (31)

1. Foxman B. Epidemiology of urinary tract infections: incidence, morbidity, and economic costs. Am J Med 113 Suppl 1A (2002) 5S-13S
2. Naber K.G., Schito G., Botto H., Palou J., and Mazzei T. Surveillance study in Europe and Brazil on clinical aspects and antimicrobial resistance epidemiology in females with cystitis (ARESC): implications for empiric therapy. Eur Urol 54 (2008) 1164-1178
3. Wagenlehner F.M., Weidner W., and Naber K.G. Emerging drugs for bacterial urinary tract infections. Expert Opin Emerg Drugs 10 (2005) 275-298
4. Grabe M, Bishop MC, Bjerklund-Johansen TE, et al. Guidelines on urological infections. European Association of Urology Web site. http://www.uroweb.org/professional-resources/guidelines/online/. Updated 2009. Accessed May 2009.
5. Hooton T.M., Scholes D., Hughes J.P., et al. A prospective study of risk factors for symptomatic urinary tract infection in young women. N Engl J Med 335 (1996) 468-474
6. Raz R., and Stamm W.E. A controlled trial of intravaginal estriol in postmenopausal women with recurrent urinary tract infections. N Engl J Med 329 (1993) 753-756
7. Raz R., Chazan B., Kennes Y., et al. Empiric use of trimethoprim-sulfamethoxazole (TMP-SMX) in the treatment of women with uncomplicated urinary tract infections, in a geographical area with a high prevalence of TMP-SMX-resistant uropathogens. Clin Infect Dis 34 (2002) 1165-1169
8. Albert X, Huertas I, Pereiró II, Sanfélix J, Gosalbes V, Perrota C. Antibiotics for preventing recurrent urinary tract infection in non-pregnant women. Cochrane Database Syst Rev 2004:CD001209.
9. Reid G. Probiotic therapy and functional foods for prevention of urinary tract infections: state of the art and science. Curr Infect Dis Rep 2 (2000) 518-522
10. Fünfstück R., Straube E., Schildbach O., and Tietz U. Prevention of reinfection by L-methionine in patients with recurrent urinary tract infection. Med Klin (Munich) 92 (1997) 574-581
11. Avorn J., Monane M., Gurwitz J.H., Glynn R.J., Choodnovskiy I., and Lipsitz L.A. Reduction of bacteriuria and pyuria after ingestion of cranberry juice. JAMA 271 (1994) 751-754
12. Jepson RG, Mihaljevic L, Craig J. Cranberries for preventing urinary tract infections. Cochrane Database Syst Rev 2004:CD001321.
13. Bessler WG, Puce K, vor dem Esche U, Kirschning C, Huber M. Immunomodulating effects of OM-89, a bacterial extract from Escherichia coli, in murine and human leukocytes. Arzneimittelforschung/Drug Research. In press.
14. Schmidhammer S., Ramoner R., Höltl L., Bartsch G., Thurnher M., and Zelle-Rieser C. An Escherichia coli-based oral vaccine against urinary tract infections potently activates human dendritic cells. Urology 60 (2002) 521-526
15. Van Pham T., Kreis B., Corradin-Betz S., Bauer J., and Mauël J. Metabolic and functional stimulation of lymphocytes and macrophages by an Escherichia coli extract (OM-89): in vitro studies. J Biol Response Mod 9 (1990) 231-240
16. Marchant A., Duchow J., and Goldman M. Adhesion molecules in antibacterial defenses: effects of bacterial extracts. Respiration 59 Suppl 3 (1992) 24-27
17. Chiavaroli C., and Moore A. An hypothesis to link the opposing immunological effects induced by the bacterial lysate OM-89 in urinary tract infection and rheumatoid arthritis. BioDrugs 20 (2006) 141-149
18. Huber M., Krauter K., Winkelmann G., et al. Immunostimulation by bacterial components: II. Efficacy studies and meta-analysis of the bacterial extract OM-89. Int J Immunopharmacol 22 (2000) 1103-1111
19. Huber M., Baier W., Serr A., and Bessler W.G. Immunogenicity of an E. coli extract after oral or intraperitoneal administration: induction of antibodies against pathogenic bacterial strains. Int J Immunopharmacol 22 (2000) 57-68
20. Lee S.J., Kim S.W., Cho Y.H., and Yoon M.S. Anti-inflammatory effect of an Escherichia coli extract in a mouse model of lipopolysaccharide-induced cystitis. World J Urol 24 (2006) 33-38
21. Bauer H.W., Alloussi S., Egger G., Blümlein H.-M., Cozma G., Schulman C.C., and on behalf of Multicenter UTI Study Group. A long-term, multicenter, double-blind study of an Escherichia coli extract (OM-89) in female patients with recurrent urinary tract infections. Eur Urol 47 (2005) 542-548
22. Hachen H.J. Oral immunotherapy in paraplegic patients with chronic urinary tract infections: a double-blind, placebo-controlled trial. J Urol 143 (1990) 759-762
23. Baertschi R., Balmer J.A., Eduah S.B., Liechti A., Lurie D., and Schams H. Bacterial extract for the prevention of recurrent urinary tract infections in pregnant women: a pilot study. Int J Immunother 19 (2003) 25-31
24. Lettgen B. Prevention of recurrent urinary tract infections in female children: OM-89 immunotherapy compared with nitrofurantoin prophylaxis in a randomized pilot study. Curr Ther Res 57 (1996) 464-475
25. Rudick C.N., Schaeffer A.J., and Thumbikat P. Experimental autoimmune prostatitis induces chronic pelvic pain. Am J Physiol Regul Integr Comp Physiol 294 (2008) R1268-R1275
26. Desireddi N.V., Campbell P.L., Stern J.A., et al. Monocyte chemoattractant protein-1 and macrophage inflammatory protein-1alpha as possible biomarkers for the chronic pelvic pain syndrome. J Urol 179 (2008) 1857-1861
27. Naber K.G., Cho Y.H., Matsumoto T., and Schaeffer A.J. Immunoactive prophylaxis of recurrent urinary tract infections: a meta-analysis. Int J Antimicrob Agents 33 (2009) 111-119
28. Tammen H. Immunobiotherapy with Uro-Vaxom in recurrent urinary tract infection. The German Urinary Tract Infection Study Group. Br J Urol 65 (1990) 6-9
29. Pisani E, Palla R, Bono AV. Double-blind randomised clinical study of OM-8930 vs placebo in patients suffering from recurrent urinary tract infections [quoted by Chiavaroli C, Moore A. An hypothesis to link the opposing immunological effects induced by the bacterial lysate OM-89 in urinary tract infection and rheumatoid arthritis. BioDrugs 2006; 20:141-9]. Geneva, Switzerland: OM PHARMA; 1992.
30. Schulman C.C., Corbusier A., Michiels H., and Taenzer H.J. Oral immunotherapy of recurrent urinary tract infections: a double-blind placebo-controlled multicenter study. J Urol 150 (1993) 917-921
31. Magasi P., Pánovics J., Illés A., and Nagy M. Uro-Vaxom and the management of recurrent urinary tract infection in adults: a randomized multicenter double-blind trial. Eur Urol 26 (1994) 137-140